How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema

Intravitreal anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular oedema (DME) may begin with several initial monthly doses. Characteristics, treatment patterns and outcomes were compa…

This post was originally published on this site